Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
Prostate and Urologic Cancer
Sponsor
National Cancer Institute (NCI)
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT00462280
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or placebo works in treating patients at high risk of melanoma.
Intervention
biopsy, laboratory biomarker analysis, lovastatin, placebo
Condition
Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Investigators
Kenneth Linden